Rein Therapeutics (RNTX) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Trading Symbol	ALRN
Entity Registrant Name	Aileron Therapeutics, Inc.
Entity Central Index Key	0001420565
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		21,589,576
Entity File Number	001-38130
Entity Tax Identification Number	13-4196017
Entity Address, Address Line One	12407 N. Mopac Expy.
Entity Address, Address Line Two	Suite 250
Entity Address, Address Line Three	#390
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78758
City Area Code	737
Local Phone Number	802-1989
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 12,042	$ 17,313
Prepaid expenses and other current assets	697	882
Restricted cash	25	25
Operating lease, right-of-use asset, current portion		46
Total current assets	12,764	18,266
Property and equipment, net	6	19
Goodwill	6,330	6,330
Intangible assets	79,200	79,200
Other non-current assets	892	2,193
Total assets	99,192	106,008
Current liabilities:
Accounts payable	2,156	1,190
Accrued expenses and other current liabilities	2,376	3,147
Operating lease liabilities, current portion		48
Total current liabilities	4,532	4,385
Deferred tax liability	3,326	3,326
Total liabilities	7,858	7,711
Commitments and contingencies (Note 15)
Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at March 31, 2024 and at December 31, 2023; 24,610 shares issued and 12,653 shares outstanding at March 31, 2024 and 24,610 shares issued and outstanding at December 31, 2023	46,584	91,410
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and 45,000,000 at December 31, 2023; 16,842,512 shares and 4,885,512 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	103	91
Additional paid-in capital	340,340	295,376
Accumulated other comprehensive loss	(63)	(63)
Accumulated deficit	(295,630)	(288,517)
Total liabilities, convertible preferred stock and stockholders' equity	$ 99,192	$ 106,008

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	5,000,000	5,000,000
Convertible preferred stock, shares issued	24,610	24,610
Convertible preferred stock, shares outstanding	12,653	24,610
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	45,000,000
Common stock, shares issued	16,842,512	4,885,512
Common stock, shares outstanding	16,842,512	4,885,512

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development	3,463	1,810
General and administrative	3,742	2,179
Restructuring and other costs	0	1,022
Total operating expenses	7,205	5,011
Loss from operations	(7,205)	(5,011)
Other income, net	92	232
Net loss	$ (7,113)	$ (4,779)
Net loss per share - basic	$ (0.86)	$ (1.05)
Net loss per share - diluted	$ (0.86)	$ (1.05)
Weighted average common shares outstanding - basic	8,301,798	4,541,167
Weighted average common shares outstanding - diluted	8,301,798	4,541,167
Comprehensive loss:
Net loss	$ (7,113)	$ (4,779)
Other comprehensive gain:
Unrealized gain on investments, net of tax of $0	0	38
Total other comprehensive gain	0	38
Total comprehensive loss	$ (7,113)	$ (4,741)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Unrealized gain on investments, tax	$ 0	$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Convertible Series X Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning balance, shares at Dec. 31, 2022			4,541,167
Beginning balance at Dec. 31, 2022	$ 18,623		$ 91	$ 291,365	$ (48)	$ (272,785)
Stock-based compensation expense	391			391
Unrealized loss on investments	38				38
Net loss	(4,779)					(4,779)
Ending balance, shares at Mar. 31, 2023			4,541,167
Ending balance at Mar. 31, 2023	$ 14,273		$ 91	291,756	(10)	(277,564)
Beginning balance, shares at Dec. 31, 2023	4,885,512		4,885,512
Beginning balance at Dec. 31, 2023	$ 98,297	$ 91,410	$ 91	295,376	(63)	(288,517)
Beginning balance, shares at Dec. 31, 2023		24,610
Issuance of common stock in connection with conversion of Series X preferred stock, value		$ (44,826)
Issuance of common stock in connection with conversion of Series X preferred stock, shares		(11,957)
Issuance of common stock in connection with conversion of Series X preferred stock			$ 12	44,814
Issuance of common stock in connection with conversion of Series X preferred stock, shares			11,957,000
Stock-based compensation expense	150			150
Unrealized loss on investments	0
Net loss	$ (7,113)					(7,113)
Ending balance, shares at Mar. 31, 2024	16,842,512		16,842,512
Ending balance at Mar. 31, 2024	$ 91,334	$ 46,584	$ 103	$ 340,340	$ (63)	$ (295,630)
Ending balance, shares at Mar. 31, 2024		12,653

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (7,113)	$ (4,779)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	59	43
Net amortization of premiums and discounts on investments	0	(103)
Stock-based compensation expense	150	391
Loss on disposition of property and equipment	0	16
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	185	247
Other assets	1,301	24
Accounts payable	966	(1,262)
Operating lease liabilities	(48)	(33)
Accrued expenses and other current liabilities	(771)	795
Net cash used in operating activities	(5,271)	(4,661)
Cash flows from investing activities:
Proceeds from sales or maturities of investments	0	7,250
Net cash provided by investing activities	0	7,250
Cash flows from financing activities:
Net (decrease) increase in cash, cash equivalents and restricted cash	(5,271)	2,589
Cash, cash equivalents and restricted cash at beginning of period	17,338	5,219
Cash, cash equivalents and restricted cash at end of period	12,067	7,808
Cash and cash equivalents at end of period	12,042	7,783
Restricted cash at end of period	25	25
Cash, cash equivalents and restricted cash at end of period	12,067	$ 7,808
Supplemental disclosure of non-cash investing and financing activities:
Conversion of Series X preferred stock into common stock shares	$ 44,826

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (7,113)	$ (4,779)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of the Business

Nature of the Business	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Nature of the Business	1 . Nature of the Business Aileron Therapeutics, Inc. (“Aileron” or the “Company”) is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. The Company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications. On October 31, 2023, Aileron acquired Lung Therapeutics, Inc. (“Lung Therapeutics” or “Lung”) pursuant to an Agreement and Plan of Merger, dated October 31, 2023 (the “Lung Acquisition Agreement”), by and among the Company, AT Merger Sub I, Inc., a Delaware corporation and its wholly owned subsidiary (“First Merger Sub”), AT Merger Sub II, LLC, a Delaware limited liability company and its wholly owned subsidiary (“Second Merger Sub”) and Lung. Pursuant to the Lung Acquisition Agreement, First Merger Sub merged with and into Lung, pursuant to which Lung was the surviving entity and became its wholly owned subsidiary (the “First Merger”). Immediately following the First Merger, Lung merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity (such merger, together with the First Merger, the “Lung Acquisition”). Lung was incorporated on November 13, 2012 under the laws of the state of Texas. Following the Lung Acquisition, the Company shifted its operating disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications with the potential to greatly improve patient outcomes over currently available treatments. Following expiration of the operating lease agreement to rent an office space for its corporate headquarters in Austin, Texas, on March 31, 2024, the Company expects to operate virtually for the foreseeable future (see Note 15 for further details). The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry, including, but not limited to the risk that the Company never achieves profitability, the need for substantial additional financing, the risk of relying on third parties, risks of clinical trial failures, dependence on key personnel, protection of proprietary technology, and compliance with government regulations. The Company’s lead product candidate, LTI-03, is being developed for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) and has completed a healthy volunteer Phase 1a clinical trial. LTI-03 is currently in a Phase 1b clinical trial in IPF patients. The Company’s second product candidate, LTI-01, is in development for loculated pleural effusion (“LPE”). The Company has completed Phase 1b and Phase 2a clinical trials in LPE patients. Liquidity and Going Concern In accordance with Accounting Standards Update (“ASU”) No. 2014-15, Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying consolidated financial statements were issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the condensed consolidated financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the consolidated financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved before the date that the consolidated financial statements are issued. The Company’s condensed consolidated financial statements have been prepared assuming that the Company will continue to operate as a going concern, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. Through March 31, 2024, the Company has financed its operations primarily through $ 145,467 in net proceeds from sales of common stock and warrants, $ 131,211 from sales of preferred stock prior to its initial public offering (“IPO”), and $ 34,910 from a collaboration agreement in 2010, and $ 18,429 in gross proceeds, less issuance costs of $ 893 , in connection with the financing following the Lung Acquisition. As of March 31, 2024, the Company had $ 12,042 in cash and cash equivalents. On May 1, 2024, Aileron entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as underwriter, relating to an underwritten offering (the “Offering”) of 4,273,505 shares of the Company’s common stock, par value $ 0.001 per share (the “Offering Shares”) and accompanying warrants (the “Offering Warrants”) to purchase 4,273,505 shares of common stock (the “Offering Warrant Shares”). All of the Offering Shares and Offering Warrants were sold by the Company by May 3, 2024 for the net proceeds from the Offering of approximately $ 17,945 , after deducting underwriting discounts and commissions and estimated offering expenses, and excluding any proceeds that may be received from exercise of the Offering Warrants (see Note 16 for further details). The Company expects to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to fund the development and commercialization of its product candidates, including its ongoing Phase 1b clinical trial of LTI-03; and for working capital and other general corporate purposes. After the Offering, management considers that, based on the Company’s current operating plan, the Company’s cash and cash equivalents o f $ 27,496 as of May 3, 2024 will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2025. Since its inception, the Company has not generated any revenue from pro duct sales and has never generated an operating profit. The Company has incurred significant losses on an aggregate basis. The Company’s net losses were $ 7,113 and $ 4,779 for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company had an accumulated deficit of $ 295,630 . These losses have resulted primarily from costs incurred in connection with research and development activities, licensing and patent investment and general and administrative costs associated with the Company’s operations. Management expects to continue to incur operating losses for the foreseeable future until the Company completes development and approval of its product candidates. The Company will continue to fund its operations primarily through utilization of its current financial resources and additional raises of capital. These conditions support the Company’s ability to continue as a going concern for at least one year from the date those condensed consolidated financial statements are issued. However, the Company could use its available capital resources sooner than it currently expects. The Company’s future viability is dependent on its ability to raise additional capital, enter into a financing, consummate a successful acquisition, merger, business combination, or a sale of assets or other transaction. If the Company becomes unable to continue as a going concern, it may have to liquidate its assets and the values it receives for its assets in liquidation or dissolution could be significantly lower than the values reflected in its consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2 . Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by ASUs of the Financial Accounting Standards Board (“FASB”). Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Lung Therapeutics, LLC, Lung Therapeutics Australia Pty Ltd, and Lung Therapeutics Limited. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the prepaid research and development expenses, and the value of stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and for the three months then ended have been prepared by the Company pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 that was filed with the SEC on April 15, 2024. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. The financial data and other information disclosed in these notes related to the three months ended March 31, 2024 and 2023 are unaudited. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period. The accompanying balance sheet as of December 31, 2023 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on April 15, 2024. The Company’s significant accounting policies are described in Note 2 to the consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2023 that was filed with the SEC on April 15, 2024. Concentration of Credit Risk and of Significant Suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains balances in operating accounts above federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents. The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relied on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could have been adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. Accounting Pronouncements Not Yet Adopted In March 2024, the FASB issued ASU 2024-02—Codification Improvements—Amendments to Remove References to the Concepts Statements, that contains amendments to the Codification that remove references to various FASB Concepts Statements. This effort facilitates Codification updates for technical corrections such as conforming amendments, clarifications to guidance, simplifications to wording or the structure of guidance, and other minor improvements. The amendments are effective for public business entities for fiscal years beginning after December 15, 2024, with early adoption permitted. Early application of the amendments in this ASU is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued (or made available for issuance). If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the effect of this ASU on its consolidated financial statements and related disclosures. In March 2024, the FASB issued ASU 2024-01—Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, to improve GAAP by adding an illustrative example that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718, Compensation—Stock Compensation. For public business entities, the amendments in this ASU are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning of the annual period that includes that interim period. The Company is currently assessing the effect of this ASU on its consolidated financial statements and related disclosures.

Business Acquisition

Business Acquisition	3 Months Ended
	Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]
Business Acquisition	3. Business Acquisition On October 31, 2023, Aileron acquired 100 % of Lung, pursuant to the Lung Acquisition Agreement. At the closing of the Lung Acquisition, Aileron issued to the stockholders of Lung 344,345 shares of its common stock (excluding 221 fractional shares from the total 344,566 shares pursuant to the Lung Acquisition Agreement) and 19,903 shares of its newly designated Series X Preferred Stock (excluding 238 fractional shares from the total 20,141 shares pursuant to the Lung Acquisition Agreement). Each share of Series X Preferred Stock is convertible into 1,000 shares of common stock. The Company paid $ 290 cash in lieu of fractional shares of both common stock and Series X Preferred Stock. In addition, Aileron assumed all Lung’s stock options ( 1,780,459 ) and all warrants ( 726,437 ) exercisable for Lung common stock immediately outstanding prior to the closing of the Lung Acquisition, each subject to adjustment pursuant to the terms of the Lung Acquisition Agreement. Immediately following the closing of the Lung Acquisition, on October 31, 2023, Aileron entered into a Stock and Warrant Purchase Agreement (the “Purchase Agreement”) with a group of accredited investors, pursuant to which Aileron issued and sold (i) an aggregate of 4,707 shares of Series X Preferred Stock, and (ii) warrants (the “PIPE Warrants”) to purchase up to an aggregate of 2,353,500 shares of Aileron common stock (the “PIPE Warrant Shares”), for an aggregate purchase price of approximately $ 18,429 , which included the conversion of certain convertible promissory notes in the aggregate principal amount of $ 1,553 issued by Lung to Bios Partners, the majority stockholder of Lung prior to the closing of the Lung Acquisition, at a 10 % discount to the per share price of the Series X Preferred Stock (the “PIPE Financing”). The PIPE Financing closed on November 2, 2023. Each share of Series X Preferred Stock is convertible into 1,000 shares of common stock. The net proceeds from the PIPE Financing of approximately $ 17,536 are expected to be used to advance Aileron’s clinical development pipeline, business development activities, working capital and other general corporate purposes. The Lung Acquisition was accounted for under the acquisition method of accounting under ASC 805, Business Combinations. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. Consideration transferred is the sum of the acquisition-date fair values of the assets transferred, the liabilities incurred by the acquirer to the former owners of the acquiree, and the equity interests issued by the acquirer to the former owners of the acquiree (except for the measurement of share-based payment awards). The Company recorded the assets acquired and liabilities assumed as of the date of the Lung Acquisition based on the information available at that date.

Fair Value of Financial Assets

Fair Value of Financial Assets	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets	4. Fair Value of Financial Assets The following tables present information about the Company’s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: March 31, 2024 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 10,954 $ — $ — $ 10,954 $ 10,954 $ — $ — $ 10,954 December 31, 2023 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 10,322 $ — $ — $ 10,322 $ 10,322 $ — $ — $ 10,322 During the three months ended March 31, 2024 and the year ended December 31, 2023 , there were no transfers between levels.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: March 31, December 31, Prepaid research and development $ 150 $ 207 Other current assets 547 675 Total prepaid expenses and other current assets $ 697 $ 882

Goodwill and Indefinite-Lived I

Goodwill and Indefinite-Lived Intangible Assets	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Indefinite-Lived Intangible Assets	6. Goodwill and Indefinite-Lived Intangible Assets $ 6,330 of goodwill and $ 79,200 of indefinite-lived intangible assets acquired in the Lung Acquisition were recorded at fair value on the Lung Acquisition date. The Company performed a qualitative assessment of goodwill and indefinite-lived intangible assets for potential impairment as of March 31, 2024, and concluded that there was no goodwill or intangible assets impairment as of March 31, 2024.

Other Assets

Other Assets	3 Months Ended
	Mar. 31, 2024
Prepaid Expense and Other Assets [Abstract]
Other Assets	7. Other Assets Other assets consisted of the following: March 31, December 31, Non-current prepaid research and development $ 839 $ 2,140 Other assets 53 53 Total other non-current assets $ 892 $ 2,193

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: March 31, December 31, External research and development services $ 913 $ 1,110 Payroll and payroll-related costs 420 1,178 Professional fees 763 653 Other 280 206 Total accrued expenses and other current liabilities $ 2,376 $ 3,147

Preferred Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Preferred Stock	9. Preferred Stock The Company is authorized to issue 5,000,000 shares of preferred stock, par value $ 0.001 per share. As of March 31, 2024, the Company had issued 24,610 shares of Series X Preferred Stock, of which 12,653 shares of Series X Preferred Stock remained outstanding. As of December 31, 2023, 24,610 shares of Series X Preferred Stock were issued and outstanding. On March 5, 2024, based upon existing beneficial ownership limitations, 11,957 shares of Series X Preferred Stock were automatically converted into 11,957,000 shares of common stock and 12,653 shares of Series X Preferred Stock (which are convertible into 12,653,000 shares of common stock) remained convertible at the option of the holder thereof, subject to certain beneficial ownership limitations (see below). On October 31, 2023, Aileron acquired Lung. Under the terms of the Lung Acquisition Agreement, at the closing of the Lung Acquisition, Aileron issued to the stockholders of Lung 344,345 shares of the common stock of Aileron, par value $ 0.001 per share, and 19,903 shares of Series X Preferred Stock. Immediately following the closing of the Lung Acquisition, on October 31, 2023, Aileron entered into the Purchase Agreement with a group of accredited investors, pursuant to which Aileron issued and sold 4,707 shares of Series X Preferred Stock and Warrants to purchase up to an aggregate of 2,353,500 shares of Aileron common stock. Refer to Note 3 for more details on the PIPE Financing in connection with the Purchase Agreement. Since the Series X Preferred Stock was sold as a unit with the PIPE Warrants according to the Purchase Agreement, the proceeds received were allocated to each instrument on a relative fair value basis. Total gross proceeds of $ 18,429 reduced by $ 893 of the issuance costs were allocated as follows: $ 16,795 to the Series X Preferred Stock and $ 741 to the PIPE Warrants. The Series X Preferred Stock and the PIPE Warrants issued in the PIPE Financing were recorded at par value of $ 0.001 . The Company evaluated the Series X Preferred Stock for liability classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity ("ASC 480"), and determined that equity treatment was appropriate because the Series X Preferred Stock did not meet the definition of the liability instruments. Specifically, the Series X Preferred Stock is not mandatorily redeemable and does not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. The Company determined that the Series X Preferred Stock would be recorded as temporary equity, based on the guidance of ASC 480, given that it is contingently redeemable. Each share of Series X Preferred Stock is convertible into 1,000 shares of Common Stock. The preferences, rights, and limitations initially applicable to the Series X Preferred Stock are set forth in the Certificate of Designation. The Series X Preferred Stock has the following characteristics: Voting Except as otherwise required by law, the Series X Preferred Stock does not have voting rights. However, as long as any shares of Series X Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series X Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series X Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or by-laws of the Company, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Preferred Stock, (ii) issue further shares of Series X Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series X Preferred Stock, or (iii) enter into any agreement with respect to any of the foregoing. Dividends Holders of Series X Preferred Stock are entitled to receive dividends on shares of Series X Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the common stock. Such dividends are not cumulative. Since the Company’s inception, no dividends have been declared or paid. Liquidation, dissolution or winding up The Series X Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. Upon liquidation, dissolution or winding up of the Company, the Series X preferred stockholders shall be entitled to receive an equivalent amount of distributions as would be paid on the common stock underlying the Series X Preferred Stock, determined on an as-converted basis, pari passu with any distributions to the common stock shareholders. Conversion The Series X Preferred Stock is convertible into common stock at a rate of 1,000 shares of common stock for every one share of Series X Preferred Stock that is converted. The Series X Preferred Stock is subject to certain beneficial ownership limitations, including that a holder of Series X Preferred Stock is prohibited from converting shares of Series X Preferred Stock into shares of common stock if, as a result of such conversion, such holder (together with its affiliates and any other persons acting as a group together with the holder or any of its affiliates) would beneficially own more than a specified percentage (to be initially set at 19.99 % and thereafter adjusted by the holder to a number not to exceed 19.99 %) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. Redemption Shares of the Series X Preferred Stock are not redeemable at the election of the holder. Maturity The Series X Preferred Stock shall be perpetual unless converted.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Common Stock	10. Common Stock On February 28, 2024, the Company held its 2023 annual meeting of stockholders (the “2023 Annual Meeting”), at which the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock of the Company from 45,000,000 to 100,000,000 shares. The Company filed the Certificate of Amendment to implement the increase in the number of authorized shares, which was effective upon filing, with the Secretary of State of the State of Delaware on February 28, 2024. The additional shares of common stock authorized by the Certificate of Amendment have rights identical to the Company’s currently outstanding common stock. As of March 31, 2024 and December 31, 2023, the Company was authorized to issue 100,000,000 and 45,000,000 shares of common stock, respectively, par value $ 0.001 per share. As of March 31, 2024, the Company had 16,842,512 shares of common stock issued and outstanding. As of December 31, 2023, the Company had 4,885,512 shares of common stock issued and outstanding. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any. As of March 31, 2024 and December 31, 2023, no dividends had been declared. In the event of liquidation or dissolution, the holders of the common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Issuance of Common Stock At the 2023 Annual Meeting, the Company’s stockholders also approved the issuance, in accordance with Nasdaq Listing Rule 5635(a), of shares of common stock, upon conversion of the Company ’ s outstanding Series X Preferred Stock. On March 5, 2024, based upon existing beneficial ownership limitations, 11,957 shares of Series X Preferred Stock were automatically converted into 11,957,000 shares of common stock and approximately 12,653 shares of Series X Preferred Stock (which are convertible into 12,653,000 shares of common stock) remained convertible at the option of the holder thereof, subject to certain beneficial ownership limitations. On October 31, 2023, Aileron acquired Lung. Under the terms of the Lung Acquisition Agreement, at the closing of the Lung Acquisition, Aileron issued to the stockholders of Lung 344,345 shares of the common stock of Aileron, par value $ 0.001 per share, and 19,903 shares of Series X Preferred Stock. Immediately following the closing of the Lung Acquisition, on October 31, 2023, Aileron entered into the Purchase Agreement with a group of accredited investors, pursuant to which Aileron issued and sold 4,707 shares of Series X Preferred Stock and PIPE Warrants to purchase up to an aggregate of 2,353,500 shares of Aileron common stock. Refer to Note 3 for more details on the PIPE Financing in connection with the Purchase Agreement. The exercise price of the PIPE Warrants is $ 4.89 per share, subject to certain price and share adjustments, including for stock splits, stock dividends, recapitalizations, subdivisions, combinations, reclassifications, noncash distributions, and cash dividends. The PIPE Warrants will be exercisable any time after May 2, 2024 and on or prior to May 2, 2027. Payment for the PIPE Warrant Shares upon exercise of the PIPE Warrants may be (i) in cash or (ii) in the event that there is no registration statement available for the resale of the PIPE Warrant Shares, by cashless exercise. Under the terms of the PIPE Warrants, the Company shall not effect the exercise of any portion of any PIPE Warrant, and a holder shall not have the right to exercise any portion of any PIPE Warrant, to the extent that after giving effect to such exercise, the holder (together with its affiliates and any other persons acting as a group together with the holder or any of its affiliates), would beneficially own in excess of a percentage elected by the holder up to 19.99 % of the number of shares of common stock outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the PIPE Warrants. However, any holder may, upon written notice to the Company, increase or decrease such percentage to any other percentage not in excess of 19.99 %; provided that any increase or decrease in such percentage will not be effective until 61 days after such notice is delivered to the Company. The Company has assessed the PIPE Warrants for appropriate equity or liability classification and determined the PIPE Warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to ASC 815, Derivatives and Hedging (“ASC 815”). The PIPE Warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the PIPE Warrants are classified as equity and accounted for as a component of additional paid-in capital at the time of issuance. The PIPE Warrants were initially recognized at their relative fair value in the amount of $ 741 at the time of issuance determined using Black-Scholes option-pricing model and will not be remeasured. As of March 31, 2024, 16,842,512 shares of common stock were issued and outstanding, no shares were held in treasury, and 24,610 shares of Series X Preferred Stock had been issued, of which 12,653 shares of Series X Preferred Stock remained outstanding. In addition, as of March 31, 2024, there were: • 12,890,000 shares of common stock reserved for issuance upon conversion of the Series X Preferred Stock; • 2,126,972 shares of common stock issuable upon the exercise of options under existing equity incentive plans; • 3,412,623 and 7,500 shares of common stock reserved for issuance under the 2021 Plan (as defined below) and 2017 Employee Stock Purchase Plan, respectively, as well as any automatic increases in the number of shares of the common stock reserved under these plans; and • 3,726,696 shares of common stock reserved for issuance upon exercise of outstanding warrants. The warrants consist of (i) warrants to purchase 646,759 shares of the Company’s common stock, with an exercise price of $ 40.00 per share, which were issued in a private placement in April 2019, which expire on April 2, 2024 ; (ii) warrants to purchase 726,437 shares of the Company’s common stock, with an exercise price of $ 5.66 , which expire on May 20, 2029 , which were assumed in connection with the Lung Acquisition, and (iii) warrants to purchase 2,353,500 shares of the Company’s common stock, with an exercise price of $ 4.89 per share, which were issued and sold in the PIPE Financing as described above and expire on May 2, 2027 . Accordingly, as of March 31, 2024, out of the 100,000,000 shares of common stock presently authorized, 39,006,303 shares are issued and outstanding or reserved for issuance and 60,993,697 shares of common stock remain available for future issuance.

Stock-Based Awards

Stock-Based Awards	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Awards	11. Stock-Based Awards As of March 31, 2024, the Company had five equity compensation plans, each of which was approved by its stockholders: 2006 Equity Incentive Plan, as amended (the “2006 Plan”), 2016 Stock Incentive Plan (the “2016 Plan”), 2017 Stock Incentive Plan (the “2017 Plan”), 2021 Stock Incentive Plan (the “2021 Plan”), and 2017 Employee Stock Purchase Plan (the “2017 ESPP”). The Company also assumed Lung’s 2013 Long-Term Incentive Plan (the “2013 Plan”) as a result of the Lung Acquisition. As of March 31, 2024, the Company had 6,693 shares to be issued upon exercise of outstanding options under the 2006 Plan; 8,404 shares to be issued upon exercise of outstanding options under the 2016 Plan, and 98,528 shares to be issued upon exercise of outstanding options under the 2017 Plan. No shares remained available for future issuance under the 2006 Plan, the 2016 Plan, or the 2017 Plan as of March 31, 2024. Under the 2021 Plan, shares that are expired, terminated, surrendered or canceled without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. The exercise price for stock options granted may not be less than the fair market value of the common stock as of the date of grant. 2021 Stock Incentive Plan The Company’s 2021 Plan was approved by the Company’s stockholders on June 15, 2021 and became effective on June 16, 2021. At the 2023 Annual Meeting, the stockholders of the Company approved an amendment (the “Plan Amendment”) to the 2021 Plan to increase the number of shares of common stock issuable under the 2021 Plan by 3,000,000 shares to 3,840,254 . On January 17, 2024, upon the recommendation of the compensation committee and subject to stockholder approval, the Company’s Board of Directors adopted the Plan Amendment. Other than increasing the number of shares issuable under the 2021 Plan, the Plan Amendment does not make any changes to the 2021 Plan. Under the 2021 Plan, the Company may grant incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, awards of restricted stock units and other stock-based awards. The Company’s employees, officers, directors, consultants and advisors are eligible to receive awards under the 2021 Plan; however, incentive stock options may only be granted to employees. The 2021 Plan is administered by the Company’s Board of Directors (the “Board”) or, at the discretion of the Board, by a committee of the Board. The number of shares of common stock covered by options and the date those options become exercisable, type of options to be granted, exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated. Stock options granted under the 2021 Plan with service-based vesting conditions generally vest over four years and may not have a duration in excess of ten years , although options have been granted with vesting terms of less than four years . The total number of shares of common stock that may be issued under the 2021 Plan was 3,841,710 as of March 31, 2024, of which 3,412,623 shares remained available for grant. The Company initially reserved 625,000 shares of common stock, plus the number of shares of common stock subject to outstanding awards under the 2017 Plan, the 2016 Plan and the 2006 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right up to 314,006 shares. 2017 Stock Incentive Plan The 2017 Plan was approved by the Company’s stockholders on June 16, 2017, and became effective on June 28, 2017. Under the 2017 Plan, the Company could grant incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, awards of restricted stock units and other stock-based awards. The Company’s employees, officers, directors, consultants and advisors were eligible to receive awards under the 2017 Plan; however, incentive stock options could only be granted to employees. The 2017 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board. The number of shares of common stock covered by options and the date those options become exercisable, type of options granted, exercise prices, vesting and other restrictions were determined at the discretion of the Board, or its committee if so delegated. Stock options granted under the 2017 Plan with service-based vesting conditions generally vest over four years and may not have a duration in excess of ten years , although options have been granted with vesting terms of less than four years . The exercise price for stock options granted may not be less than the fair market value of the common stock as of the date of grant. As of the effective date of the 2021 Plan, the Board determined to grant no further awards under the 2017 Plan. Shares that are expired, terminated, surrendered or canceled without having been fully exercised under the 2017 Plan will be available for future awards under the 2021 Plan. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards under the 2021 Plan. 2017 Employee Stock Purchase Plan On June 16, 2017, the Company’s stockholders approved the 2017 ESPP, which became effective on June 28, 2017. Under the 2017 ESPP, the number of shares of common stock that may be issued under the 2017 ESPP will automatically increase on each January 1, beginning with the fiscal year ended December 31, 2018 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2027, equal to the least of (i) 31,120 shares, (ii) 1 % of the outstanding shares of common stock on such date and (iii) an amount determined by the Company’s Board. On January 1, 2023 and January 1, 2024, no additional shares were reserved for issuance under the 2017 ESPP pursuant to this provision. 7,500 shares remained available for future issuance under the 2017 ESPP as of March 31, 2024. 2013 Stock Incentive Plan The Company assumed the 2013 Plan as a result of the Lung Acquisition. In October 2013, Lung’s Board of Directors (“Lung Board”) approved the 2013 Plan to provide long-term incentives for its employees, non-employee directors and certain consultants. As of March 31, 2024, 1,780,459 shares were reserved to be issued upon exercise of options outstanding under the 2013 Plan. These options were assumed by the Company in connection with the Lung Acquisition. Before the Lung Acquisition, the 2013 Plan was administered by the Lung Board or, at the discretion of the Lung Board, by a committee of the Lung Board. The exercise prices, vesting and other restrictions were determined at the discretion of the Lung Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100 % of the fair market value of the share of common stock on the date of grant and the term of stock option may not be greater than ten years . The contractual term for stock option awards is ten years . The vesting periods for equity awards were determined by the Lung Board, but generally were four years . The contractual term for stock option awards is ten years . Following the closing of the Lung Acquisition on October 31, 2023, no further awards can be granted under the 2013 Plan. Stock Option Valuation The assumptions that the Company used to determine the grant-date fair value of the stock options granted to employees and directors during the three months ended March 31, 2024 and 2023 were as follows, presented on a weighted average basis: Three Months Ended March 31, 2024 2023 Risk-free interest rate 4.26 % 2.33 % Expected term (in years) 5.5 6.1 Expected volatility 105.7 % 94.4 % Expected dividend yield 0 % 0 % Stock Options The following table summarizes the Company’s stock option activity since January 1, 2023: Number of Weighted Weighted Aggregate Outstanding at December 31, 2023 2,212,102 $ 7.42 6.0 $ 2,905 Granted 5,450 4.72 — Exercised — — — — Forfeited/Canceled ( 26,297 ) 4.07 — — Expired ( 64,283 ) 37.56 — Outstanding at March 31, 2024 2,126,972 6.54 5.8 8,895 Options exercisable at March 31, 2024 1,882,612 $ 6.38 5.6 $ 8,193 Options vested and expected to vest at March 31, 2024 2,118,381 $ 6.55 5.8 $ 8,861 Options exercisable at December 31, 2023 1,882,191 $ 7.46 5.8 $ 2,631 Options vested and expected to vest at December 31, 2023 2,209,420 $ 7.41 6.0 $ 2,904 The weighted average grant-date fair value of stock options granted during the three months ended March 31, 2024 was $ 3.82 . There were no options granted to employees or directors during the three months ended March 31, 2023. The aggregate fair value of stock options that vested during the three months ended March 31, 2024 and 2023, was $ 228 and $ 405 , respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. There were no stock options exercised during the three months ended March 31, 2024 and 2023. Stock-Based Compensation The Company recorded stock-based compensation expense related to stock options in the following expense categories of its statements of operations and comprehensive loss: Three Months Ended March 31, 2024 2023 Research and development expenses $ 39 $ 119 General and administrative expenses 111 272 $ 150 $ 391 As of March 31, 2024 , the Company had an aggregate of $ 525 of unrecognized stock-based compensation expense, which it expects to recognize over a weighted average period of 1.65 years. On March 11, 2024, the Company and Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer ("CEO") of the Company, effective as of March 11, 2024. Dr. Aivado remains a member of the Company’s Board. Dr. Aivado’s resignation from the Company was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. As a non-employee director, following the separation date, Dr. Aivado will be compensated in accordance with the terms of the Company’s non-employee director compensation program. In addition, Dr. Aivado will continue to vest in all unvested stock option awards pursuant to the original vesting terms. The resignation of Dr. Aivado as CEO was considered a significant reduction in service and his original awards were deemed to have been modified and accounted for as a Type III modification with no material effect on these condensed consolidated financial statements.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss per Share	12. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows : Three Months Ended March 31, 2024 2023 Numerator: Net loss $ ( 7,113 ) $ ( 4,779 ) Denominator: Weighted average common shares outstanding—basic and diluted 8,301,798 4,541,167 Net loss per share attributable to common stockholders—basic and diluted $ ( 0.86 ) $ ( 1.05 ) The Company’s potential dilutive securities, which include stock options as of March 31, 2024 and 2023 , have been excluded from the computation of diluted net loss per share attributable to common stockholders whenever the effect of including them would be to reduce the net loss per share. In periods where there is a net loss, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended March 31, 2024 2023 Options to purchase common stock 2,126,972 506,986 Warrants to issue shares of common stock 3,726,696 646,759 Series X Preferred Stock issued and outstanding, as converted 12,653,000 — Total 18,506,668 1,153,745

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes As of March 31, 2024, the Company has not recorded any U.S. federal or state income tax benefits for either the net losses it has incurred or its earned research and orphan drug credits, due to the uncertainty of realizing a benefit from those items in the future.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	14. Related Party Transactions On March 5, 2024, entities and individuals affiliated with Bios Partners (collectively, the “Bios Entities”) converted 1,476 shares of the Company’s Series X Preferred Stock into 1,476,000 shares of common stock. After the conversion, as of March 31, 2024, the Bios Entities owned 1,673,305 shares of the Company’s common stock resulting in a beneficial ownership of 9.9 % of the Company’s outstanding common stock. On March 5, 2024, the Board of Regents of the University of Texas System, or UT System, on behalf of University of Texas Health Science Center at Tyler, or UTHSCT, converted 503 shares of the Company’s Series X Preferred Stock into 503,000 shares of the Company's common stock. On the same date, UT System, on behalf of University of Texas in Austin, or UT Austin, converted 1,277 shares of the Company’s Series X Preferred Stock into 1,277,000 shares of the Company's common stock. Given the effect of the conversion, as of March 31, 2024, UT System and its affiliates beneficially owned 1,812,627 shares of the Company’s common stock resulting in a beneficial ownership of 10.8 % of the Company’s outstanding common stock. The Company also has several license agreements with UT System and its affiliates, as disclosed in Note 15.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Operating Leases On August 16, 2021, Lung entered into an operating lease agreement to rent approximately 6,455 square feet of office space for its corporate headquarters in Austin, Texas, beginning on October 1, 2021. The lease expired March 31, 2024 , and the Company did not renew the lease. Following expiration of the lease, the Company is operating virtually, and expects to do so for the foreseeable future. Legal Proceedings The Company may from time to time be party to litigation arising in the ordinary course of business. As of March 31, 2024, the Company was not party to any legal proceedings and no material legal proceedings are currently pending or, to the best of the Company’s knowledge, threatened. Intellectual Property Licenses Harvard and Dana-Farber Agreement In August 2006, the Company entered into an exclusive license agreement with President and Fellows of Harvard College (“Harvard”) and Dana-Farber Cancer Institute (“DFCI”). The agreement granted the Company an exclusive worldwide license, with the right to sublicense, under specified patents and patent applications to develop, obtain regulatory approval for and commercialize specified product candidates based on cell-permeating peptides. Under the agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize one or more licensed products and to achieve specified milestone events by specified dates. In connection with entering into the agreement, the Company paid an upfront license fee and issued to Harvard and DFCI shares of its common stock. In February 2010, the agreement was amended and restated (the “Harvard/DFCI agreement”) under which additional patent rights were added to the scope of the license agreement and the annual license maintenance fees were increased. Under the Harvard/DFCI agreement, the Company is obligated to make aggregate milestones payments of up to $ 7,700 per licensed therapeutic product upon the Company’s achievement of specified clinical, regulatory and sales milestones with respect to such product and up to $ 700 per licensed diagnostic product upon the Company’s achievement of specified regulatory and sales milestones with respect to such product. In addition, the Company is obligated to pay royalties of low single-digit percentages on annual net sales of licensed products sold by the Company, its affiliates or its sublicensees. The royalties are payable on a product-by-product and country-by-country basis and may be reduced in specified circumstances. In addition, the agreement obligates the Company to pay a percentage, up to the mid-twenties, of fees received by the Company in connection with its sublicense of the licensed products. In accordance with the terms of the agreement, the Company’s sublicense payment obligations may be subject to specified reductions. The Harvard/DFCI agreement requires the Company to pay annual license maintenance fees of $ 110 each year, which was reduced to $ 35 starting in 2023. Any payments made in connection with the annual license maintenance fees will be credited against any royalties due. As of March 31, 2024, the Company had not developed a commercial product using the licensed technologies and no royalties under the agreement had been paid or were due. Under the Harvard/DFCI agreement, the Company is responsible for all patent expenses related to the prosecution and maintenance of the licensed patents and applications in-licensed under the agreement as well as cost reimbursement of amounts incurred for all documented patent-related expenses. The agreement will expire on a product-by-product and country-by-country basis upon the last to expire of any valid patent claim pertaining to licensed products covered under the agreement. The Company incurred $ 9 and $ nil license maintenance fees in the three months ended March 31, 2024 and 2023, respectively. Agreement with the University of Texas Health Science Center at Tyler In June 2013, Lung entered into a patent and technology license agreement with UT System, on behalf of UTHSCT. The patent and technology license agreement with UT System (the “UTHSCT Agreement”) provides Lung access to patents and technology related to the development of LTI-01 and LTI-03. As part of the UTHSCT Agreement, Lung has (i) a royalty-bearing, exclusive license under the patent rights to manufacture, distribute, and sell certain intellectual property; (ii) a non-exclusive license under the technology rights to manufacture, distribute and sell the licensed product; and (iii) a sublicensing right that allows Lung to grant sublicenses to affiliates and third parties to use the licensed product in the field of use and approved territories outlined in the UTHSCT Agreement. In December 2013, the UTHSCT Agreement was amended and restated to include certain patents in all fields worldwide. In May 2017, the UTHSCT Agreement was amended and restated to modify the specific milestone criteria. In consideration of the UTHSCT Agreement, Lung granted UT System (via UTHSCT and UT Horizon Fund affiliates) (i) 2,000,000 shares of Lung common stock and (ii) 400,000 shares of Lung non-convertible preferred stock. On February 6, 2015, UT System exchanged the 400,000 shares of Lung non-convertible preferred stock for 4,000,000 shares of Lung common stock. In addition, Lung agreed to pay past and ongoing patent expenses, and Lung owes UTHSCT sublicensing fees, assignment fees, and single digit royalties on worldwide net product sales, with fixed minimum royalty payments that started in 2015. Pursuant to the UTHSCT Agreement, Lung is required to use diligent efforts to commercialize the licensed technology as soon as commercially practicable, including maintaining active research and development, regulatory, marketing and sales program, all as commercially reasonable. The Company may terminate the UTHSCT Agreement for convenience with 90 days’ notice. UTHSCT may also terminate the UTHSCT Agreement, but only if the Company breaches the terms of the agreement. The Company did not incur any expense in the three months ended March 31, 2024 and 2023. Agreement with the University of Texas at Austin In May 2015, Lung entered into a patent license agreement with UT Austin on behalf of UT System. This license agreement with UT Austin (the “UT Austin 6607 Agreement”) relates to the patent rights to polypeptide therapeutics and uses thereof. Pursuant to the UT Austin 6607 Agreement Lung has (i) a royalty-bearing, exclusive license under the patent rights to manufacture, distribute, and sell the licensed product; and (ii) a sublicensing right that allows Lung to grant sublicenses to affiliates and third parties to use the licensed product in the field of use and approved territories outlined in the agreement. The UT Austin 6607 Agreement was amended and restated in January 2017, November 2018, and June 2019. The amendments related to extension of milestone payment dates and specific terminology around the milestone achievement criteria. In consideration of the UT Austin 6607 Agreement, Lung agreed to pay past and ongoing patent expenses, milestone fees upon certain development and regulatory milestone events, annual license fees, tiered sublicense fees, assignment fees, low single digit royalties on net sales and a Food and Drug Administration (“FDA”) Priority Review Voucher fee if Lung sells or transfers this voucher. Pursuant to the UT Austin 6607 Agreement, Lung is required to use diligent efforts to commercialize the licensed products, including maintaining active research and development, regulatory, marketing and sales program. Moreover, Lung is required to meet certain development and regulatory milestones by specific dates. The Company may terminate the UT Austin 6607 Agreement for convenience with 90 days’ notice. UT Austin may also terminate the UT Austin 6607 Agreement, but only if the Company breaches the terms of the agreement. The Company did not incur any expense in the three months ended March 31, 2024 and 2023. Agreement with Medical University of South Carolina In March 2016, Lung entered into a license agreement with Medical University of South Carolina Foundation for Research Development, or MUSC. Pursuant to this license agreement with MUSC (the “MUSC Agreement”) Lung has patent rights related to protecting against lung fibrosis by up regulating Cav1. The MUSC Agreement granted (i) a royalty-bearing, exclusive license under the patent rights to make, use and sell the license product; and (ii) a sublicensing right that allows Lung to grant sublicenses to affiliates and third parties to use the licensed product in the field of use and approved territories outlined in the agreement. In September 2018, the agreement was amended and restated to include definitions of related methods, related products and related rights. In consideration of the MUSC Agreement, Lung agreed to pay a non-refundable license fee, patent expenses, milestone fees upon certain development, regulatory and commercial milestone events, sublicense fees, assignment fees and low single digit royalties on net sales, with a fixed minimum royalty payment starting in 2019 and a transaction fee upon Lung’s liquidation. Pursuant to the MUSC Agreement, Lung is required to use diligent efforts to develop, manufacture and sell the licensed products. The Company may terminate the MUSC Agreement for convenience by providing a written notice to MUSC effective 90 days following the receipt of notice, and either party may terminate the agreement for a breach of contract. The Company incurred $ 25 and $ nil license fee in the three months ended March 31, 2024 and 2023, respectively. Agreement with Vivarta Therapeutics LLC In March 2018, Lung entered into a license agreement with Vivarta Therapeutics, LLC, or Vivarta. This license agreement with Vivarta (the “Vivarta Agreement”) relates to intellectual property relating to epithelial sodium channel inhibitors and methods to treat pulmonary disease. Pursuant to the Vivarta Agreement Lung has (i) a royalty-bearing, exclusive license under the intellectual property rights to make, use and sell the licensed product, and (ii) a sublicensing right that allows Lung to grant sublicenses to affiliates and third parties to use the licensed product in the field of use and approved territories outlined in the agreement. In consideration for the Vivarta Agreement, Lung agreed to grant Vivarta a warrant to purchase an aggregate of 75,000 shares of Lung common stock for $ 0.12 per share, to pay a license fee of $ 10,000 upon the Vivarta Agreement effective date and $ 40,000 within 30 days of the receipt of a positive freedom to operate analysis from legal counsel. Lung also agreed to pay patent expenses, milestone fees upon certain development and regulatory milestone events, sublicense fees, assignment fees and low single digit royalties on net sales. Pursuant to the Vivarta Agreement, Lung is required to use diligent efforts to develop, manufacture and sell the licensed products. The Company may terminate the Vivarta Agreement for convenience by providing a written notice to Vivarta effective 90 days following the receipt of notice, and either party may terminate the agreement for a breach of contract. The Company did not incur any expense in the three months ended March 31, 2024 and 2023. Manufacturing Commitments As of March 31, 2024, the Company has non-cancellable purchase obligations and a prepaid balance with its contract manufacturer in the amount of $ 2,339 and $ 131 , respectively. Aggregate future service and purchase commitments with manufacturer as of March 31, 2024 are as follows: March 31, 2024 2024 $ - 2025 and thereafter 2,339 Total purchase commitments 2,339 Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it had not accrued any liabilities related to such obligations in its consolidated financial statements as of March 31, 2024 or December 31, 2023 .

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Event	16. Subsequent Event As discussed in Note 1 – Nature of the Business – Liquidity and Going Concern, on May 1, 2024, the Company entered into the Underwriting Agreement and sold 4,273,505 Offering Shares and 4,273,505 Offering Warrants to purchase 4,273,505 shares of the Company’s common stock to several investors for the net proceeds from the Offering of approximately $ 17,945 , after deducting underwriting discounts and commissions and estimated offering expenses, and excluding any proceeds that may be received from exercise of the Offering Warrants. The Offering closed on May 3, 2024. Each Offering Share was offered and sold together with an accompanying Offering Warrant at a combined offering price of $ 4.68 . Each Offering Warrant has an exercise price per share of common stock equal to $ 4.68 . Each Offering Warrant is immediately exercisable and may be exercised until the third anniversary of the issuance date. Each Offering Warrant is exercisable solely by means of a cash exercise, except that an Offering Warrant is exercisable via cashless exercise if at the time of exercise, a registration statement registering the issuance of Offering Warrant Shares is not then effective or the prospectus is not available for the issuance of Offering Warrant Shares. Each Offering Warrant is callable by the Company during the ten trading day period after the date that is 30 days following the public announcement by the Company of the top-line results from the Phase 1b clinical trial of LTI-03 in patients with IPF, including a statement that there were no drug-related adverse events that resulted in a discontinuation of the trial (the “Trigger Date”). Subject to certain exceptions, in the event that the Offering Warrants are outstanding, if, after the Trigger Date, then the Company may, within ten trading days of the Trigger Date, upon notice (a “Call Notice”), call for cancellation of the Offering Warrants for which a notice of exercise has not yet been delivered for consideration equal to $ 0.001 per Offering Warrant Share; provided that the Company may only deliver such Call Notice if the volume-weighted average price of its shares of common stock exceeds the exercise price of the Offering Warrants on the trading day immediately prior to the date the Company delivers the Call Notice. Any Offering Warrant subject to such Call Notice for which a notice of exercise shall not have been received by the Call Date (as hereinafter defined) will be cancelled at 6:30 p.m. (New York City time) on the ten th trading day after the date the Company sends the Call Notice. On May 8, 2024, the Bios Entities provided notice to the Company and converted 421 shares of the Company’s Series X Preferred Stock into 421,000 shares of common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by ASUs of the Financial Accounting Standards Board (“FASB”). Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and for the three months then ended have been prepared by the Company pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 that was filed with the SEC on April 15, 2024. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. The financial data and other information disclosed in these notes related to the three months ended March 31, 2024 and 2023 are unaudited. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period. The accompanying balance sheet as of December 31, 2023 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on April 15, 2024. The Company’s significant accounting policies are described in Note 2 to the consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2023 that was filed with the SEC on April 15, 2024.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Lung Therapeutics, LLC, Lung Therapeutics Australia Pty Ltd, and Lung Therapeutics Limited. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the prepaid research and development expenses, and the value of stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Concentration of Credit Risk and of Significant Suppliers	Concentration of Credit Risk and of Significant Suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains balances in operating accounts above federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents. The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relied on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could have been adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.
Recently Issued Accounting Pronouncements	Accounting Pronouncements Not Yet Adopted In March 2024, the FASB issued ASU 2024-02—Codification Improvements—Amendments to Remove References to the Concepts Statements, that contains amendments to the Codification that remove references to various FASB Concepts Statements. This effort facilitates Codification updates for technical corrections such as conforming amendments, clarifications to guidance, simplifications to wording or the structure of guidance, and other minor improvements. The amendments are effective for public business entities for fiscal years beginning after December 15, 2024, with early adoption permitted. Early application of the amendments in this ASU is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued (or made available for issuance). If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the effect of this ASU on its consolidated financial statements and related disclosures. In March 2024, the FASB issued ASU 2024-01—Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, to improve GAAP by adding an illustrative example that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718, Compensation—Stock Compensation. For public business entities, the amendments in this ASU are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning of the annual period that includes that interim period. The Company is currently assessing the effect of this ASU on its consolidated financial statements and related disclosures.

Fair Value of Financial Assets

Fair Value of Financial Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of Assets Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: March 31, 2024 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 10,954 $ — $ — $ 10,954 $ 10,954 $ — $ — $ 10,954 December 31, 2023 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 10,322 $ — $ — $ 10,322 $ 10,322 $ — $ — $ 10,322

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid and Other Current Assets	Prepaid expenses and other current assets consisted of the following: March 31, December 31, Prepaid research and development $ 150 $ 207 Other current assets 547 675 Total prepaid expenses and other current assets $ 697 $ 882

Other Assets (Tables)

Other Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Prepaid Expense and Other Assets [Abstract]
Schedule of Other Assets	Other assets consisted of the following: March 31, December 31, Non-current prepaid research and development $ 839 $ 2,140 Other assets 53 53 Total other non-current assets $ 892 $ 2,193

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: March 31, December 31, External research and development services $ 913 $ 1,110 Payroll and payroll-related costs 420 1,178 Professional fees 763 653 Other 280 206 Total accrued expenses and other current liabilities $ 2,376 $ 3,147

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Valuation Assumptions of Stock Options Granted	The assumptions that the Company used to determine the grant-date fair value of the stock options granted to employees and directors during the three months ended March 31, 2024 and 2023 were as follows, presented on a weighted average basis: Three Months Ended March 31, 2024 2023 Risk-free interest rate 4.26 % 2.33 % Expected term (in years) 5.5 6.1 Expected volatility 105.7 % 94.4 % Expected dividend yield 0 % 0 %
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity since January 1, 2023: Number of Weighted Weighted Aggregate Outstanding at December 31, 2023 2,212,102 $ 7.42 6.0 $ 2,905 Granted 5,450 4.72 — Exercised — — — — Forfeited/Canceled ( 26,297 ) 4.07 — — Expired ( 64,283 ) 37.56 — Outstanding at March 31, 2024 2,126,972 6.54 5.8 8,895 Options exercisable at March 31, 2024 1,882,612 $ 6.38 5.6 $ 8,193 Options vested and expected to vest at March 31, 2024 2,118,381 $ 6.55 5.8 $ 8,861 Options exercisable at December 31, 2023 1,882,191 $ 7.46 5.8 $ 2,631 Options vested and expected to vest at December 31, 2023 2,209,420 $ 7.41 6.0 $ 2,904
Summary of Stock Based Compensation Expense	The Company recorded stock-based compensation expense related to stock options in the following expense categories of its statements of operations and comprehensive loss: Three Months Ended March 31, 2024 2023 Research and development expenses $ 39 $ 119 General and administrative expenses 111 272 $ 150 $ 391

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share Attributable to Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows : Three Months Ended March 31, 2024 2023 Numerator: Net loss $ ( 7,113 ) $ ( 4,779 ) Denominator: Weighted average common shares outstanding—basic and diluted 8,301,798 4,541,167 Net loss per share attributable to common stockholders—basic and diluted $ ( 0.86 ) $ ( 1.05 )
Summary of Potential Common Shares Excluded from Calculation of Diluted Net Loss per Share	The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended March 31, 2024 2023 Options to purchase common stock 2,126,972 506,986 Warrants to issue shares of common stock 3,726,696 646,759 Series X Preferred Stock issued and outstanding, as converted 12,653,000 — Total 18,506,668 1,153,745

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Aggregate Future Service and Purchase Commitments with Manufacturer	Aggregate future service and purchase commitments with manufacturer as of March 31, 2024 are as follows: March 31, 2024 2024 $ - 2025 and thereafter 2,339 Total purchase commitments 2,339

Nature of the Business - Additi

Nature of the Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	May 03, 2024	May 01, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Oct. 31, 2023
Class of Stock [Line Items]
Proceeds from collaboration agreement			$ 34,910
Cash and cash equivalents			$ 12,042	$ 7,783	$ 17,313
Number of stock sold			2,353,500
Common stock, par value			$ 0.001		$ 0.001
Net loss			$ (7,113)	$ (4,779)
Accumulated deficit			(295,630)		$ (288,517)
Subsequent Event [Member]
Class of Stock [Line Items]
Cash and cash equivalents	$ 27,496
Underwriting Agreement [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Net proceeds from offering	$ 17,945	$ 17,945
Common stock, par value		$ 0.001
Lung Acquisition [Member]
Class of Stock [Line Items]
Proceeds from sales of stock			18,429
Cash and cash equivalents			$ 12,042
Number of stock sold			726,437
Common stock, par value						$ 0.001
Issuance costs			$ 893
Offering Shares [Member]
Class of Stock [Line Items]
Proceeds from sales of stock			145,467
Offering Shares [Member] | Underwriting Agreement [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of stock sold		4,273,505
Warrants to purchase shares of common stock		4,273,505
Offering Shares [Member] | Offering Warrant Shares [Member] | Underwriting Agreement [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Warrants to purchase shares of common stock		4,273,505
Preferred Stock [Member]
Class of Stock [Line Items]
Proceeds from sales of stock			$ 131,211

Business Acquisition - Addition

Business Acquisition - Additional Information (Detail) - Lung Acquisition [Member] $ in Thousands	Oct. 31, 2023 USD ($) shares
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired	100%
Purchase Agreement [Member]
Business Acquisition [Line Items]
Net proceeds from the Financing expected to be used to advance | $	$ 17,536
Convertible Promissory Notes [Member] | Purchase Agreement [Member]
Business Acquisition [Line Items]
Debt Conversion, Converted Instrument, Amount | $	$ 1,553
Common Stock [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	344,566
Common Stock [Member] | Whole Share [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	344,345
Common Stock [Member] | Fractional Share [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	221
Series X Preferred Stock [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	20,141
Convertible Preferred Stock, Shares Issued upon Conversion	1,000
Series X Preferred Stock [Member] | Purchase Agreement [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	4,707
Percentage of discount to per share price	10%
Convertible Preferred Stock, Shares Issued upon Conversion	1,000
Series X Preferred Stock [Member] | Whole Share [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	19,903
Series X Preferred Stock [Member] | Fractional Share [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	238
Warrants [Member]
Business Acquisition [Line Items]
Business acquisition number of shares exercisable	(726,437)
PIPE Warrants [Member] | Purchase Agreement [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,353,500
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | $	$ 18,429
Stock Options [Member]
Business Acquisition [Line Items]
Business acquisition number of shares exercisable	(1,780,459)
Common Stock and Series X Preferred Stock [Member]
Business Acquisition [Line Items]
Business acquisition cash in lieu of fractional shares | $	$ 290

Fair Value of Financial Asset_2

Fair Value of Financial Assets - Summary of Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total Fair Value of Financial Instruments	$ 10,954	$ 10,322
Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total Fair Value of Financial Instruments	10,954	10,322
Money Market Funds [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash equivalents	10,954	10,322
Money Market Funds [Member] | Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash equivalents	$ 10,954	$ 10,322

Fair Value of Financial Asset_3

Fair Value of Financial Assets - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value, assets transfers into (out of) Level 3	$ 0	$ 0

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid research and development	$ 150	$ 207
Other current assets	547	675
Total prepaid expenses and other current assets	$ 697	$ 882

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Property and equipment, net	$ 6	$ 19

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 6		$ 19
Gain (loss) on sale of property and equipment	$ 0	$ (16)

Goodwill and Indefinite-Lived_2

Goodwill and Indefinite-Lived Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Indefinite-Lived Intangible Assets [Line Items]
Goodwill	$ 6,330,000	$ 6,330,000
Indefinite-lived intangible assets acquired	79,200,000
Impairment of goodwill	0
Impairment of indefinite-lived intangible assets	$ 0

Other Assets - Schedule of Othe

Other Assets - Schedule of Other Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Prepaid Expense and Other Assets [Abstract]
Non-current prepaid research and development	$ 839	$ 2,140
Other assets	53	53
Total other non-current assets	$ 892	$ 2,193

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
External research and development services	$ 913	$ 1,110
Payroll and payroll-related costs	420	1,178
Professional fees	763	653
Other	280	206
Total accrued expenses and other current liabilities	$ 2,376	$ 3,147

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Mar. 05, 2024	Oct. 31, 2023	Mar. 31, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Common stock, shares issued			16,842,512	4,885,512
Common stock, par value			$ 0.001	$ 0.001
Issuance costs			$ 893
Proceeds from the PIPE transaction			$ 741
Common Stock [Member]
Class of Stock [Line Items]
Preferred Stock is automatically convertible into common stock	11,957,000
Preferred Stock is convertible into common stock			12,653,000
PIPE Warrants [Member]
Class of Stock [Line Items]
Preferred stock, par value			$ 0.001
Lung Acquisition [Member]
Class of Stock [Line Items]
Common stock, shares issued		344,345
Common stock, par value		$ 0.001
Lung Acquisition [Member] | Maximum [Member] | Common Warrants [Member]
Class of Stock [Line Items]
Aggregate number of shares issued and sold		2,353,500
Series X Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			5,000,000
Preferred stock, par value			$ 0.001
Preferred stock, shares issued			24,610	24,610
Preferred stock, shares outstanding			12,653	24,610
Conversion of stock shares converted	11,957
Conversion of stock shares issued			12,653
Preferred Stock is convertible into common stock			1,000
Gross proceeds from issuance of preferred stock			$ 18,429
Proceeds from issuance of preferred stock			$ 16,795
Preferred stock, dividends declared			$ 0
Preferred stock, dividends paid			$ 0
Preferred stock, convertible, shares issuable beneficial ownership as a percentage			19.99%
Series X Preferred Stock [Member] | Lung Acquisition [Member]
Class of Stock [Line Items]
Preferred stock, shares issued		19,903
Series X Preferred Stock [Member] | Lung Acquisition [Member] | Purchase Agreement [Member]
Class of Stock [Line Items]
Aggregate number of shares issued and sold		4,707

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	12 Months Ended
	Mar. 05, 2024	Oct. 31, 2023	Mar. 31, 2024	Dec. 31, 2023	Feb. 28, 2024	Jan. 01, 2024	Mar. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized			100,000,000	45,000,000	100,000,000
Common stock, par value			$ 0.001	$ 0.001
Common stock, shares issued			16,842,512	4,885,512
Common stock, shares outstanding			16,842,512	4,885,512
Common stock voting rights			Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
Common stock, dividends declared			$ 0	$ 0
Aggregate number of common stock shares issued and sold			2,353,500
Treasury stock			0
Shares issued, outstanding and reserved for issuance			39,006,303
Series X Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock shares converted	11,957
Preferred stock, shares issued			24,610	24,610
Conversion of stock shares issued			12,653
Preferred Stock is convertible into common stock			1,000
Preferred stock, shares outstanding			12,653	24,610
Common stock reserved for issuance			12,890,000
Warrants and Rights Outstanding, Maturity Date			May 02, 2027
Warrants exercise price			$ 4.89
Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares outstanding			16,842,512	4,885,512			4,541,167		4,541,167
Preferred Stock is automatically convertible into common stock	11,957,000
Preferred Stock is convertible into common stock			12,653,000
Stock remained available for future issuance			60,993,697
Common Warrants [Member]
Class of Stock [Line Items]
Warrants exercise price		$ 4.89
Warrants [Member]
Class of Stock [Line Items]
Common stock reserved for issuance			3,726,696
PIPE Warrants [Member]
Class of Stock [Line Items]
Issuance of warrants			$ 741
PIPE Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Percentage of common stock share outstanding			19.99%
Existing Equity Incentive Plans [Member]
Class of Stock [Line Items]
Common stock reserved for issuance			2,126,972
2021 Stock Incentive Plan [Member]
Class of Stock [Line Items]
Common stock reserved for issuance			3,412,623
Stock remained available for future issuance			3,841,710
2017 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Common stock reserved for issuance			7,500			0		0
Stock remained available for future issuance			7,500
Lung Acquisition [Member]
Class of Stock [Line Items]
Common stock, par value		$ 0.001
Common stock, shares issued		344,345
Aggregate number of common stock shares issued and sold			726,437
Warrants and Rights Outstanding, Maturity Date			May 20, 2029
Warrants exercise price			$ 5.66
Lung Acquisition [Member] | Series X Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued		19,903
Aggregate number of common stock shares issued and sold		4,707
Lung Acquisition [Member] | PIPE Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Aggregate number of common stock shares issued and sold		2,353,500
Private Placement [Member]
Class of Stock [Line Items]
Aggregate number of common stock shares issued and sold			646,759
Warrants and Rights Outstanding, Maturity Date			Apr. 02, 2024
Warrants exercise price			$ 40

Restructuring and Other Costs -

Restructuring and Other Costs - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 0	$ 1,022

Stock-Based Awards - Additional

Stock-Based Awards - Additional Information (Detail) $ / shares in Units, $ in Thousands			3 Months Ended
	Oct. 31, 2023 shares	Jun. 16, 2017 shares	Mar. 31, 2024 USD ($) Plan $ / shares shares	Mar. 31, 2023 USD ($) shares	Feb. 28, 2024 shares	Jan. 01, 2024 shares	Dec. 31, 2023 shares	Jan. 01, 2023 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant-date fair value of stock options | $ / shares			$ 3.82
Number of options granted to employees or directors			5,450	0
Aggregate fair value of stock options vested | $			$ 228	$ 405
Aggregate unrecognized stock-based compensation expense | $			$ 525
Unrecognized stock-based compensation expense, weighted average period expects for recognition			1 year 7 months 24 days
Number of stock options exercised			0	0
Number of equity compensation plans | Plan			5
Number of shares, issued upon exercise of outstanding options			2,126,972				2,212,102
2021 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option granted vesting period			4 years
Number of shares, available for grant			3,841,710
Number of shares remained available for grant			3,412,623
Stock reserved for future issuance			3,412,623
Increase in common stock			3,840,254		3,000,000
2021 Stock Incentive Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option granted vesting period			4 years
Stock option expiration period			10 years
2017 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option granted vesting period			4 years
Stock reserved for future issuance			625,000
Number of shares, issued upon exercise of outstanding options			98,528
Number of shares remained available for future issuance			0
2017 Stock Incentive Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period			10 years
2006 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Contractual repurchase right, shares			314,006
Number of shares, issued upon exercise of outstanding options			6,693
Number of shares remained available for future issuance			0
2016 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, issued upon exercise of outstanding options			8,404
Number of shares remained available for future issuance			0
2017 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, available for grant			7,500
Stock reserved for future issuance			7,500			0		0
Percentage of common stock shares outstanding		1%
Stock incentive plan description			On June 16, 2017, the Company’s stockholders approved the 2017 ESPP, which became effective on June 28, 2017. Under the 2017 ESPP, the number of shares of common stock that may be issued under the 2017 ESPP will automatically increase on each January 1, beginning with the fiscal year ended December 31, 2018 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2027, equal to the least of (i) 31,120 shares, (ii) 1% of the outstanding shares of common stock on such date and (iii) an amount determined by the Company’s Board. On January 1, 2023 and January 1, 2024, no additional shares were reserved for issuance under the 2017 ESPP pursuant to this provision. 7,500 shares remained available for future issuance under the 2017 ESPP as of March 31, 2024.
Maximum annual increase in common stock reserved for future issuance		31,120
2013 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options granted to employees or directors	0
2013 Stock Incentive Plan [Member] | Lung Acquisition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option granted vesting period			4 years
2013 Stock Incentive Plan [Member] | Options Outstanding [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, available for grant			1,780,459
Contractual terms of stock option awards			10 years
2013 Stock Incentive Plan [Member] | Options Outstanding [Member] | Lung Acquisition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Contractual terms of stock option awards			10 years
2013 Stock Incentive Plan [Member] | Maximum [Member] | Options Outstanding [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Contractual terms of stock option awards			10 years
2013 Stock Incentive Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of fair market value of common stock			100%

Stock-Based Awards - Valuation

Stock-Based Awards - Valuation Assumptions of Stock Options Granted (Detail)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	4.26%	2.33%
Expected term (in years)	5 years 6 months	6 years 1 month 6 days
Expected volatility	105.70%	94.40%
Expected dividend yield	0%	0%

Stock-Based Awards - Summary of

Stock-Based Awards - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Number of Shares, Beginning balance	2,212,102
Number of Shares, Granted	5,450	0
Number of Shares, Forfeited/Canceled	(26,297)
Number of Shares, Expired	(64,283)
Number of Shares, Ending balance	2,126,972		2,212,102
Number of Shares, Options exercisable	1,882,612		1,882,191
Number of Shares, Options vested and expected to vest	2,118,381		2,209,420
Weighted Average Exercise Price, Beginning balance	$ 7.42
Weighted Average Exercise Price, Granted	4.72
Weighted Average Exercise Price, Forfeited/Canceled	4.07
Weighted Average Exercise Price, Expired	37.56
Weighted Average Exercise Price, Ending balance	6.54		$ 7.42
Weighted Average Exercise Price, Options exercisable	6.38		7.46
Weighted Average Exercise Price, Options vested and expected to vest	$ 6.55		$ 7.41
Weighted Average Remaining Contractual Term, Outstanding	5 years 9 months 18 days		6 years
Weighted Average Remaining Contractual Term, Options exercisable	5 years 7 months 6 days		5 years 9 months 18 days
Weighted Average Remaining Contractual Term, Options vested and expected to vest	5 years 9 months 18 days		6 years
Aggregate Intrinsic Value, Beginning balance	$ 2,905
Aggregate Intrinsic Value, Ending balance	8,895		$ 2,905
Aggregate Intrinsic Value, Options exercisable	8,193		2,631
Aggregate Intrinsic Value, Options vested and expected to vest	$ 8,861		$ 2,904

Stock-Based Awards - Summary _2

Stock-Based Awards - Summary of Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 150	$ 391
Research and Development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	39	119
General and Administrative [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 111	$ 272

Net Loss per Share - Basic and

Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net loss	$ (7,113)	$ (4,779)
Denominator:
Weighted average common shares outstanding - basic	8,301,798	4,541,167
Weighted average common shares outstanding - diluted	8,301,798	4,541,167
Net loss per share - basic	$ (0.86)	$ (1.05)
Net loss per share - diluted	$ (0.86)	$ (1.05)

Net Loss per Share - Summary of

Net Loss per Share - Summary of Potential Common Shares Excluded from Calculation of Diluted Net Loss per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share	18,506,668	1,153,745
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share	2,126,972	506,986
Warrants To Issue Shares Of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share	3,726,696	646,759
Series X Preferred Stock Issued And Outstanding, As Converted [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share	12,653,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - shares	Mar. 05, 2024	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Number of shares owned		16,842,512	4,885,512
Common Stock [Member]
Related Party Transaction [Line Items]
Preferred Stock is automatically convertible into common stock	11,957,000
Number of shares owned		16,842,512	4,885,512	4,541,167	4,541,167
Bios Entities [Member]
Related Party Transaction [Line Items]
Number of shares owned		1,673,305
Percentage of beneficial ownership		9.90%
Bios Entities [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Preferred Stock is automatically convertible into common stock	1,476,000
UTHSCT [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Preferred Stock is automatically convertible into common stock	503,000
UT Austin [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Preferred Stock is automatically convertible into common stock	1,277,000
UT System and Its Affiliates [Member]
Related Party Transaction [Line Items]
Number of shares owned		1,812,627
Percentage of beneficial ownership		10.80%
Series X Preferred Stock [Member]
Related Party Transaction [Line Items]
Conversion of stock shares converted	11,957
Series X Preferred Stock [Member] | Bios Entities [Member]
Related Party Transaction [Line Items]
Conversion of stock shares converted	1,476
Series X Preferred Stock [Member] | UTHSCT [Member]
Related Party Transaction [Line Items]
Conversion of stock shares converted	503
Series X Preferred Stock [Member] | UT Austin [Member]
Related Party Transaction [Line Items]
Conversion of stock shares converted	1,277

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended		12 Months Ended
	Aug. 16, 2021 ft²	Feb. 06, 2015 shares	Mar. 31, 2018 USD ($) $ / shares shares	Jun. 30, 2013 shares	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Feb. 28, 2010 USD ($)
Other Commitments [Line Items]
Non-cancellable purchase obligations					$ 2,339
Contract obligation, prepaid amount					131
Harvard and Dana-Farber Agreement [Member] | Therapeutic Product [Member]
Other Commitments [Line Items]
Aggregate milestones payments								$ 7,700
Harvard and Dana-Farber Agreement [Member] | Diagnostic Product [Member]
Other Commitments [Line Items]
Aggregate milestones payments								$ 700
Harvard and Dana-Farber Agreement [Member] | License [Member]
Other Commitments [Line Items]
Annual license maintenance fees							$ 35
Harvard and Dana-Farber Agreement [Member] | License and Maintenance [Member]
Other Commitments [Line Items]
Annual license maintenance fees					9	$ 0	$ 110
Operating Lease Agreement [Member]
Other Commitments [Line Items]
Area of land | ft²	6,455
Lease expiration date	Mar. 31, 2024
UTHSCT Agreement [Member] | Common Stock [Member]
Other Commitments [Line Items]
Shares granted in consideration | shares		4,000,000		2,000,000
UTHSCT Agreement [Member] | Non-convertible preferred stock [Member]
Other Commitments [Line Items]
Shares granted in consideration | shares		400,000		400,000
MUSC Agreement [Member] | License [Member]
Other Commitments [Line Items]
Annual license maintenance fees					$ 25	$ 0
Vivarta Therapeutics LLC [Member]
Other Commitments [Line Items]
License fee on agreement effective date			$ 10,000
License fee on receipt of positive freedom to operate analysis from legal counsel			$ 40,000
Vivarta Therapeutics LLC [Member] | Common Stock [Member]
Other Commitments [Line Items]
Issuance of common stock warrant | shares			75,000
Warrant per share | $ / shares			$ 0.12

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Aggregate Future Service and Purchase Commitments with Manufacturer (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2025 and thereafter	$ 2,339
Total purchase commitments	$ 2,339

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) $ / shares in Units, $ in Thousands					3 Months Ended
	May 08, 2024 shares	May 03, 2024 USD ($)	May 01, 2024 USD ($) Days $ / shares shares	Mar. 05, 2024 shares	Mar. 31, 2024 $ / shares shares
Subsequent Event [Line Items]
Number of stock sold					2,353,500
Series X Preferred Stock [Member]
Subsequent Event [Line Items]
Warrants exercise price | $ / shares					$ 4.89
Conversion of stock shares converted				11,957
Common Stock [Member]
Subsequent Event [Line Items]
Preferred stock convertible into common stock				11,957,000
Subsequent Event [Member] | Series X Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of stock shares converted	421
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Offering price | $ / shares			$ 4.68
Warrants exercise price | $ / shares			$ 4.68
Preferred stock convertible into common stock	421,000
Subsequent Event [Member] | Underwriting Agreement [Member]
Subsequent Event [Line Items]
Net proceeds from offering | $		$ 17,945	$ 17,945
Number of trading days | Days			10
Notice period			30 days
Warrants exercise price | $ / shares			$ 0.001
Subsequent Event [Member] | Underwriting Agreement [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of stock sold			4,273,505
Warrants issued			4,273,505
Warrants to purchase shares of common stock			4,273,505